NeuroOne Patent Portfolio Expansion FAQ
Summary
NeuroOne Medical Technologies has significantly expanded its patent portfolio with recent patent grants and allowances from both the U.S. and European patent offices. This expansion signals opportunities for broadening the company's technology platform for neurological disorder treatments.
What is the main announcement from NeuroOne?
NeuroOne announced successful additions to its growing patent portfolio, including a granted patent in Europe, an issued patent in the U.S., and a Notice of Allowance for another U.S. patent application.
What specific patents were granted or allowed?
The European Patent Office granted EP4013481 for spinal cord stimulation systems, the USPTO issued U.S. Patent 12,435,407 for methods of making probe devices, and the USPTO issued a Notice of Allowance for U.S. Patent Application 17/860,232 covering probe devices with temperature sensors.
Why is this patent expansion significant for NeuroOne?
The growing IP portfolio signals further opportunity for expansion of the company’s technology platform and demonstrates progress in protecting their innovative medical technologies for neurological disorders.
What technologies do these new patents cover?
The patents cover novel electrode devices with temperature sensors, spinal cord stimulation devices with deployable electrode arrays, and methods for making neural probe and spinal cord stimulation devices.
How does the temperature sensor technology benefit patients?
According to CEO Dave Rosa, temperature control is an integral feature of the OneRF Ablation System that provides a critical safety measure for brain ablations in patients suffering from seizures.
What is the significance of the European patent for spinal cord stimulation?
The European patent features a percutaneously placed paddle electrode designed to save patients from having to undergo surgical incisions to treat lower back pain.
What is NeuroOne’s overall patent portfolio status?
In addition to these new patents, NeuroOne’s portfolio includes four additional issued U.S. patents, seven additional pending U.S. applications, and eight pending foreign applications covering various thin-film electrode technologies.
What medical conditions does NeuroOne focus on treating?
NeuroOne develops solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other neurological disorders.
Where can I find more information about NeuroOne?
For more information, visit nmtc1.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 251495